🌿 Tirzepatide — the dual agonist
Tirzepatide (brand name Mounjaro for diabetes, Zepbound for weight loss) targets two receptors simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone that plays a role in fat storage and energy balance.
By activating both pathways at once, Tirzepatide produces a stronger effect than GLP-1 alone. In the SURMOUNT-1 trial, participants lost an average of 20.9% of body weight at the highest dose — the largest average weight loss ever recorded in a pharmaceutical trial at that time. Some participants lost over 25%.
By activating both pathways at once, Tirzepatide produces a stronger effect than GLP-1 alone. In the SURMOUNT-1 trial, participants lost an average of 20.9% of body weight at the highest dose — the largest average weight loss ever recorded in a pharmaceutical trial at that time. Some participants lost over 25%.
1️⃣ Retatrutide — the triple agonist
Retatrutide takes it further. It targets three receptors: GLP-1, GIP, and glucagon. Glucagon receptor activation increases energy expenditure — meaning the body burns more calories even at rest.
Phase 2 trial results published in 2023 showed participants losing an average of 24.2% of body weight over 48 weeks at the highest dose. Some participants approached 30%. These numbers had never been seen before outside of surgical intervention.
Retatrutide is still in clinical trials as of 2025 and is not yet approved for prescription use. Phase 3 trials are underway.
Phase 2 trial results published in 2023 showed participants losing an average of 24.2% of body weight over 48 weeks at the highest dose. Some participants approached 30%. These numbers had never been seen before outside of surgical intervention.
Retatrutide is still in clinical trials as of 2025 and is not yet approved for prescription use. Phase 3 trials are underway.
2️⃣ How to think about the difference
Receptors targeted1 1 (GLP-1) -> (Semaglutide): Avg. weight loss ~15–17%
Receptors targeted1 2 (GLP-1 + GIP) -> Tirzepatide : Avg. weight loss ~21%
Receptors targeted1 3 (GLP-1 + GIP + Glucagon) -> Retatrutide : Avg. weight loss ~24%
~21%~24% (Phase 2)
Receptors targeted1 2 (GLP-1 + GIP) -> Tirzepatide : Avg. weight loss ~21%
Receptors targeted1 3 (GLP-1 + GIP + Glucagon) -> Retatrutide : Avg. weight loss ~24%
~21%~24% (Phase 2)
3️⃣ What to know
More receptors targeted does not automatically mean better for every person. Individual response varies significantly.
The best choice depends on your health history, goals, and what a qualified provider recommends for you specifically.
Want a protocol built around these peptides? → See the True BioCare Membership
The best choice depends on your health history, goals, and what a qualified provider recommends for you specifically.
Want a protocol built around these peptides? → See the True BioCare Membership